Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
An endemic belt of Chronic Kidney Disease of unknown origin (CKDu) has been recently reported from central India from our Centre. The prevalence and characteristics of Mineral Bone Disease (MBD) in patients with CKDu have not been described. This study aims to find out the prevalence and characteristics of MBD in patients of CKDu in Central India and compare it with the age, sex, and stage of CKD matched CKD controls of known aetiology.
This study was conducted from April 2023 to September 2024 in a tertiary care hospital in Central India. Fifty-five patients each with CKDu and age, sex, and stage of CKD matched CKD controls of known aetiology above the age of 18 years were recruited. Socio-demographic data, medical, personal, family, and drug history were recorded in structured proforma. Serum samples were analyzed for mineral bone disease were levels of Calcium (Ca), Phosphorus(P), Vitamin D(25 hydroxy vitamin D),iPTH, and alkaline phosphatase (ALP).
The majority of participants were males (n=41, 74.5%), and over the age of 50 years (55.07±11 33years). Twenty-five patients (45.5%) had stage 5 CKD, while 30.9% (n=17) had stage 4 CKD and 23.6% (n=13) had stage 3 CKD. Amongst controls, 25 (45.4%) had CKD due to presumed glomerulonephritis, while 30 (54.5%) had CKD due to diabetic nephropathy. The median eGFR was 17.0 (IQR: 7.00-29.0) ml/min/1.73m2. CKDu patients belonged more to rural areas (n=42, 67.7% vs n=20, 32.3%, p<0.0001) and were less likely to be hypertensive (n=5, 9.1% vs n=52, 94.5%, p<0.0001). A smaller number of patients in the CKDu group were on Calcium (n=20, 36.6 % vs n=34, 61.8%, p=0.008), calcitriol (n=9, 16.4% vs n=19, 34.5%, p=0.029), and sevelamer (n=9, 16.4% vs n=19, 34.5%, p=0.029) treatment at the time of enrolment.
Eighty percent (n=44) of patients with CKDu had abnormalities in serum bone markers, with 63.6% (n=35) having high turnover bone disease and 16.4 %(n=9 having low turnover bone disease. Forty-two (77.8%) patients with CKD of known origin had abnormalities in serum bone markers, with 57.8% (n=26) having high turnover bone disease and 29.1 %(n=16 having low turnover disease. The difference was not statistically significant.
Abdominal X-ray revealed aortic calcification in nine participants (16.4%) in both groups. 99mTc-sestamibi scintigraphy revealed parathyroid adenoma in nine (n=9, 16.4 % vs n=5, 9.1%, p=0.25) and parathyroid hyperplasia in twelve patients (n=12, 21.8 % vs n=14, 25.5%, p=0.65).
The prevalence of CKD MBD in patients with CKDu was 80%, with most having high bone turnover
